Hot Biotech Sector: Mid-Caps Have Both M&A And Pipeline Premiums

M&A has been a major driver of bio-pharmaceutical stocks and the buyout of Syngeva by Alexion for $8.4B last week showed that there is a lot of value in pipelines that fit with the acquirer.